NCT05561309View on ClinicalTrials.gov

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Total Knee Arthroplasty
Interventions
DRUG

HR18034;Ropivacaine Hydrochloride Injection

"Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution"

Trial Locations (1)

523059

Dongguan People's Hospital, Dongguan

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY